Trial Profile
Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAB08 in Patients With Systemic Lupus Erythematosus, Not Adequately Controlled With Current Concomitant Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Theralizumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors TheraMAB
- 21 May 2018 Status changed from recruiting to discontinued.
- 05 Dec 2016 Status changed from not yet recruiting to recruiting.
- 29 Mar 2016 New trial record